New Combo Therapy Gives Myeloma Patients 80% 2-Year Win Rate

A new immunotherapy combination is helping eight out of ten multiple myeloma patients live two years without their cancer getting worse, doubling the success rate of standard treatment.

The international trial involving over 860 patients offers fresh hope for people fighting this challenging blood cancer.